Dynamic42 GmbH has concluded a seven-digit start-up financing round. The company, which spun off from the «Center of Sepsis Control and Care» (CSCC) of the University Hospital Jena in March 2018, was able to convince the investors bm‑t beteiligungsmanagement thüringen gmbh (bm|t), Mittelständische Beteiligungsgesellschaft Thüringen mbH (MBG) and Sparkasse Jena-Saale-Holzland to invest in the round. Dynamic42 GmbH offers its customers miniaturized human organ models (so-called micro-physiological systems) in order to carry out drug toxicity tests. With the investment, Dynamic42 GmbH will progress the development of its products and services, grow the company infrastructure and personnel, strengthen its IP basis, and expand the sales organisation.
April, 8 2020 The Jena-based biotech company «Dynamic42» raised a seven-digit investment
The human immune system plays an important role in drug development. Dynamic42 GmbH is able to integrate components of the immune system into its human organ models and to investigate their influence on drug compatibility. The customer can then draw initial conclusions about the toxicity of drug candidates in humans before conducting animal experiments in the preclinical phase of drug development and decide whether the development can be continued or should be stopped. In this way, Dynamic42 contributes to increased drug safety, bringing promising drug candidates to market faster and reducing the costs of drug development and animal testing. Dynamic42 has already received several awards for this innovative solution.
Dynamic42 GmbH was founded on March 12, 2018 as a spin-off from the Center for Sepsis Control and Care (CSCC) of the University Hospital Jena. Currently, the company is located in the BioInstrumentezentrum on the Beutenberg in Jena. Dynamic42 GmbH markets and develops human micro-physiological systems (MPS) / organ-on-chip models with integrated immune system components for the research and testing of pharmaceutical products, novel therapies such as nanoparticles, chemical and food additives.
bm|t is the first address for investments in Thuringia, Germany. bm|t invests in start-up teams and companies in the Free State with a clear aim of generating positive investment returns. This is how innovation and economic growth in Thuringia are financed. bm|t currently manages eight funds with a total volume of over 400 million euros and invests in innovative companies in nearly all sectors and in all phases of company development — from the start-up and growth phases to buyouts and other succession cases.
As a strong and reliable partner, Mittelständische Beteiligungsgesellschaft Thüringen mbH (MBG) offers small and medium-sized companies mezzanine or equity investments in the early- and growth-stage as well as in succession cases. Companies thus have a good basis for solid development and sustainable growth.
The Sparkasse has been rooted in the region since 1828 and knows the wishes and objectives of the people and companies. As the largest regional financial partner, it is also important to the Sparkasse to ensure a better quality of life in the region: through the progressive digitalisation of its services, the expansion of its advisory services, public support programmes and financing. Supporting the economy, education, sport and culture through material and financial contributions is an important part of its role. For this reason, Sparkasse Jena-Saale-Holzland will continue to support business start-ups, thus preparing the ground for the jobs of the future. Recently, the Sparkasse, with the Business Angels Club Jena e.V., has established a platform for start-ups and private investors. The strong regional know-how is thus bundled through good networking and is intended to support the region´s dynamic start-up scene.